Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.
Athira Pharma, Inc. (NASDAQ: ATHA) is a late clinical-stage biopharmaceutical company based in the Seattle, Washington area, dedicated to developing small molecule therapeutics aimed at restoring neuronal health and slowing neurodegeneration. Athira's innovative pipeline includes several promising compounds, particularly targeting the neurotrophic hepatocyte growth factor (HGF) system, which plays a crucial role in nervous system maintenance and repair.
The company’s lead candidate, Fosgonimeton (ATH-1017), is a subcutaneously administered small molecule designed to positively modulate the HGF/MET system. It is currently being evaluated in the Phase 2/3 LIFT-AD clinical trial for the treatment of mild-to-moderate Alzheimer’s disease, with topline data expected in the second half of 2024. Fosgonimeton has shown potential in enhancing neuroprotective, neurotrophic, and anti-inflammatory pathways, which are critical in combating neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.
In addition to Fosgonimeton, Athira’s pipeline includes ATH-1105 and ATH-1020, both designed to be orally available treatments enhancing the HGF/MET system. ATH-1105 is particularly promising in preclinical models of amyotrophic lateral sclerosis (ALS), demonstrating significant neuroprotective effects, enhanced survival, and improved motor and nerve functions. The company plans to initiate first-in-human studies for ATH-1105 in the first half of 2024.
Athira's research is bolstered by funding from notable organizations such as the Alzheimer’s Drug Discovery Foundation, Washington’s Life Sciences Discovery Fund, and Dolby Family Ventures. This support underscores the company’s strong financial position and its capacity to advance its therapeutic candidates through key development milestones.
Recent updates highlight the therapeutic potential of Athira’s small molecules. For instance, fosgonimeton has demonstrated promising results in preclinical models of Alzheimer’s and Parkinson’s diseases, showing neuroprotective effects and improvement in cognitive and motor functions. Additionally, ATH-1105's preclinical studies have shown consistent beneficial effects in ALS models, reinforcing Athira’s approach and commitment to developing novel therapies for neurodegenerative diseases.
Athira is also active in the scientific community, regularly presenting its findings at major conferences and publishing in peer-reviewed journals. The company’s efforts are focused on leveraging its patented technologies to develop cost-effective treatments that address the root causes of neurodegenerative diseases, setting it apart from competitors that primarily target disease symptoms.
For more information about Athira Pharma, Inc., visit www.athira.com and follow the company on Facebook, LinkedIn, X (formerly known as Twitter), and Instagram.
Athira Pharma, Inc. (NASDAQ: ATHA) revealed significant findings from its Phase 2 ACT-AD trial and new preclinical data during the AAN 2023 Annual Meeting. A post hoc analysis showed that patients treated with fosgonimeton exhibited a notable improvement in Mini-Mental State Examination (MMSE) scores (+1.6 pts, p=0.0350) and a decrease in neurodegeneration biomarkers. Additionally, preclinical data on ATH-1105 indicated prolonged survival and improved motor function in ALS mouse models. Athira continues to advance its exploration of the HGF/MET neurotrophic system as a potential treatment for neurodegenerative diseases, positioning ATHA for future clinical evaluation.
Athira Pharma, a biopharmaceutical company, announced upcoming presentations at the American Academy of Neurology (AAN) Annual Meeting, scheduled for April 22-27, 2023, in Boston. The presentations will feature new clinical data from the completed Phase 2 ACT-AD trial of fosgonimeton for Alzheimer's disease, showcasing improvements in cognitive measures and plasma biomarkers. Additionally, preclinical research will support the therapeutic potential of fosgonimeton and ATH-1105 in neurodegenerative conditions, including ALS. The oral presentations will be led by Dr. Kevin Church and Dr. Hans J. Moebius on April 24 and 25, respectively. A poster presentation on ATH-1105's impact on motor function in an ALS model will occur on April 25. All presentations will be accessible on Athira's website post-event.
FAQ
What is the current stock price of Athira Pharma (ATHA)?
What is the market cap of Athira Pharma (ATHA)?
What is Athira Pharma, Inc.?
What are Athira's lead compounds?
What is the focus of Athira's research?
When are the next significant milestones for Athira?
Who funds Athira's research?
What differentiates Athira's approach from other companies?
What is Fosgonimeton?
What recent achievements has Athira reported?
How does Athira contribute to the scientific community?
Where can I find more information about Athira Pharma?
